Phaseline

Targets › CHKA

CHKA (Choline kinase alpha): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Other, Psychiatry, Oncology; next expected readout Jul 2027.

Plays a key role in phospholipid biosynthesis by catalyzing the phosphorylation of free choline to phosphocholine, the first step in phosphatidylcholine biosynthesis. Also phosphorylates ethanolamine, thereby contributing to phosphatidylethanolamine biosynthesis. (UniProt, P35790)

Open in Phaseline: the race on CHKA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Andrei Iagaru18F Fluorocholine
Fluorine-18 labeled choline PET tracer
CHKAPhase 2Parathyroid AdenomaJul 2027
Jeff WozniakCholine Bitartrate
Choline supplementation, a precursor for acetylcholine and phosphatidylcholine synthesis
CHKAPhase 2Fetal Alcohol Spectrum DisordersJul 2027
University of Colorado, DenverCholine (Phosphatidylcholine)
Choline/phosphatidylcholine supplementation to support fetal brain development
CHKAPhase 1Child DevelopmentApr 2029

Conditions

Fetal Alcohol Spectrum Disorders (1) Child Development (1) Parathyroid Adenoma (1)

Modalities

small molecule (2), mixed (1)

Companies

Jeff Wozniak (1) University of Colorado, Denver (1) Andrei Iagaru (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.